NEWS

Q’Apel Medical Announces CE Mark Approval for Armadillo SelectFlex™ Neur...

Fremont, CA – January 13, 2025 – Q’Apel Medical (Q’Apel), a privately held medical device company focused on revolutionizing neurovascular interventions, today announced it has received CE mark certification for its Armadillo SelectFlex™ Neurovascular Access System. The first-of-its-kind 7F system features the patented SelectFlex™ Technology and is indicated for the introduction of interventional devices into the neurovasculature.  

MicroVention Rebrands to Terumo Neuro – Reflects Expanded Focus and Stra...

ALISO VIEJO, Calif.--( BUSINESS WIRE )--MicroVention, Inc., a global leader in neurovascular innovation and a wholly owned subsidiary of Terumo Corporation, today announced its official rebranding to Terumo Neuro, effective immediately. This name change signifies a new chapter in the company’s evolution while maintaining its unwavering commitment to the creation and commercialization of groundbreaking innovations in neurovascular care.  

Vesalio launches pVasc Thrombectomy System in the U.S. for peripheral oc...

Introducing pVasc™ mechanical thrombectomy system for the safe and effective non-surgical removal of occlusions from the peripheral vasculature Plano, Texas - (September 4, 2024)Vesalio announces the U.S. commercialization of pVasc™ Thrombectomy System for non-surgically removing peripheral occlusions. pVasc targets the full range of embolisms from soft, acute clots to fibrin-rich, calcified ones, enabling a fast and safe removal. Its unique Drop Zone™ technology traps, retains and securely removes thrombus to restore flow in patients suffering from acute limb ischemia (ALI) and other conditions related to peripheral artery disease (PAD).  

VESALIO introduces NeVa NET 4.0 mm following international success of Ne...

In NeVa NET™, Distal Embolic Filtration and Drop Zone™ technologies work together to enhance clot capture and retention, providing effective recanalization in ischemic stroke thrombectomy. The new NeVa NET 4.0, following the success of the 5.5 mm version, is designed to offer clinicians an advanced tool for improving first-pass rates and reducing distal embolization.

Sensome signs exclusive commercial distribution agreement for clot-sensi...

First distribution agreement for Sensome’s smart clot-sensing guidewire technology used in ischemic stroke treatment.Cosmotec to make upfront equity investment in Sensome

Evasc Neurovascular Announces Successful First Case with eCLIPs Short La...

First-in-human data for sensome clot-sensing guidewire used in ischemic...

Vesalio appoints CFO and announces company headquarters in Dallas, Texas

Vesalio hires J.D. McCulloch as Chief Financial Officer and announces the establishment of the company’s headquarters in Dallas, Texas.

Sim&Cure achieves CE Marking for Sim&Size product under New Medical Devi...

Montpellier, 2024/03/11 – Sim&Cure, a leading innovator in the neurovascular field, is proud to announce that its innovative Sim&Size™ product has once more attained CE Certification, this time in accordance with the latest Medical Device Regulation (EU MDR 2017/745), underscoring our commitment to meeting evolving regulatory standards.

Sensome announces initiation of clinical trial assessing its tissue micr...

PARIS, FRANCE - FEBRUARY 12TH, 2024 – Sensome, the company pioneering the connected medical device revolution with the world’s smallest biological tissue sensor, announced today enrollment of the first patients into a feasibility clinical study using the Clotild® Smart Guidewire in peripheral artery disease (PAD). Clotild® was designated a breakthrough medical device for use in brain arteries by the FDA in 2021.